LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

Search

Omeros Corp

Open

SectorGezondheidszorg

4.07 -0.73

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.98

Max

4.17

Belangrijke statistieken

By Trading Economics

Inkomsten

8M

-25M

Winstmarge

-8,121.359

Werknemers

202

EBITDA

9.3M

-26M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+123.33% upside

Dividenden

By Dow Jones

Volgende Winsten

12 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

8.6M

287M

Vorige openingsprijs

4.8

Vorige sluitingsprijs

4.07

Nieuwssentiment

By Acuity

46%

54%

177 / 371 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Omeros Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 sep 2025, 17:03 UTC

Belangrijke Marktbewegers

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sep 2025, 16:49 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

GD Culture Shares Drop After Deal for Pallas Capital

16 sep 2025, 16:11 UTC

Belangrijke Marktbewegers

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sep 2025, 23:40 UTC

Marktinformatie

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sep 2025, 23:34 UTC

Marktinformatie

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sep 2025, 23:20 UTC

Marktinformatie

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sep 2025, 21:10 UTC

Acquisities, Fusies, Overnames

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sep 2025, 20:51 UTC

Marktinformatie

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sep 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

16 sep 2025, 20:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

16 sep 2025, 20:25 UTC

Winsten

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sep 2025, 20:24 UTC

Winsten

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sep 2025, 19:19 UTC

Marktinformatie

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sep 2025, 18:52 UTC

Marktinformatie

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sep 2025, 18:44 UTC

Marktinformatie

Global Equities Roundup: Market Talk

16 sep 2025, 18:44 UTC

Marktinformatie

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sep 2025, 18:40 UTC

Acquisities, Fusies, Overnames

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sep 2025, 18:38 UTC

Marktinformatie

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sep 2025, 18:19 UTC

Marktinformatie

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sep 2025, 18:01 UTC

Marktinformatie

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sep 2025, 17:34 UTC

Marktinformatie

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sep 2025, 16:53 UTC

Winsten

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sep 2025, 16:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

16 sep 2025, 16:15 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Commodities Roundup: Market Talk

16 sep 2025, 16:09 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Global Energy Roundup: Market Talk

16 sep 2025, 16:09 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sep 2025, 15:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

16 sep 2025, 15:35 UTC

Marktinformatie

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sep 2025, 15:22 UTC

Marktinformatie

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sep 2025, 15:21 UTC

Marktinformatie

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Peer Vergelijking

Prijswijziging

Omeros Corp Prognose

Koersdoel

By TipRanks

123.33% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 9 USD  123.33%

Hoogste 9 USD

Laagste 9 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Omeros Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technische score

By Trading Central

6.265 / 7.49Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bullish Evidence

Sentiment

By Acuity

177 / 371 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat